Researchers receive $9M NCI grant for imaging tech in clinical trials

Of adaptive and factorial designs
A biostatistician’s interpretation of last week’s ODAC

At its most recent meeting, the FDA Oncologic Drugs Advisory Committee focused on perioperative clinical trials, which the agency defined as neoadjuvant phase followed by surgery and continuing with adjuvant treatment using the same experimental agent (The Cancer Letter, July 26, 2024).

Language barriers hinder diverse recruitment to clinical trials

Underrepresentation of racial and ethnic minority populations in cancer clinical trials persists partly because translation and interpretation services and resources are unavailable or inadequate in the United States, according to a Children’s Oncology Group study led by Columbia University School of Nursing.

August 02, 2024

Vol.50 No.31

Drugs & Targets

Expanded access program opens in the U.S. for TLX101-CDx, Telix’s investigational glioma imaging agent

Telix opened an expanded access program in the United States for TLX101-CDx (Pixclara, 18F-floretyrosine or 18F-FET) an investigational positron emission tomography agent for imaging progressive or recurrent glioma, following FDA agreement to proceed.

August 02, 2024

Vol.50 No.31

Regulatory News

ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications

The FDA Oncologic Drugs Advisory Committee July 25 voted unanimously to set more rigorous standards for new trials for approval of perioperative indications of cancer drugs.

July 26, 2024

Vol.50 No.30

By Jacquelyn Cobb and Paul Goldberg

Clinical Roundup

New payment code and Medicare payment implemented for AI cancer imaging device

Avenda Health, an AI healthcare company, announced the Centers for Medicare & Medicaid Services has assigned a national payment rate for the company’s innovative prostate cancer mapping technology, Unfold AI.

July 26, 2024

Vol.50 No.30

In Brief

Sarah Bigelow named executive director of Tulane Cancer Center Clinical Trials Office

Sarah Bigelow was named executive director of the Clinical Trials Office at the Tulane Cancer Center.

July 05, 2024

Vol.50 No.27

Researchers receive $9M NCI grant for imaging tech in clinical trials

YOU MAY BE INTERESTED IN

Of adaptive and factorial designs
A biostatistician’s interpretation of last week’s ODAC

Language barriers hinder diverse recruitment to clinical trials

Expanded access program opens in the U.S. for TLX101-CDx, Telix’s investigational glioma imaging agent

ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications

New payment code and Medicare payment implemented for AI cancer imaging device

Sarah Bigelow named executive director of Tulane Cancer Center Clinical Trials Office

Renew today!

Subscriber content

Login

Researchers receive $9M NCI grant for imaging tech in clinical trials

YOU MAY BE INTERESTED IN

Of adaptive and factorial designsA biostatistician’s interpretation of last week’s ODAC

Language barriers hinder diverse recruitment to clinical trials

Expanded access program opens in the U.S. for TLX101-CDx, Telix’s investigational glioma imaging agent

ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications

New payment code and Medicare payment implemented for AI cancer imaging device

Sarah Bigelow named executive director of Tulane Cancer Center Clinical Trials Office

Login

Of adaptive and factorial designs
A biostatistician’s interpretation of last week’s ODAC